|
| |
| | | 56288 | | 06.05.2004 | | Bristol-Myers Squibb SA | | 18.08.2005 | | | | | 31.12.2023 | | | | | | 08.03. | | 06.02.2024 | | 08.03. | | IP |
| | Seq.-No. | Product | Description | Galenic form | ATC-classification | |
|---|
| 03 | Reyataz 150 mg | Kapseln | Capsules (Atazanavir 150 mg) | J05AE08 | CI | | 04 | Reyataz 200 mg | Kapseln | Capsules (Atazanavir 200 mg) | J05AE08 | CI | | 05 | Reyataz 300 mg | Kapseln | Capsules (Atazanavir 300 mg) | J05AE08 | CI |
|
|
|
